News

Analyst Maintains Optimism on Las Vegas Sands Stock Growth

Analyst Maintains Optimism on Las Vegas Sands Stock Growth

Las Vegas Sands Corp Receives Positive Price Target Update

JPMorgan recently increased its price target for Las Vegas Sands Corp (NYSE: LVS) to $60 from a previous $53, while keeping an Overweight rating on the stock. This update suggests that analysts are viewing the company’s future positively, particularly concerning its earnings before interest, taxes, depreciation, and amortization (EBITDA), especially in Macau.

Positive Adjustments to Macau EBITDA Projections

The updated EBITDA forecast for the company's Macau properties for the third quarter has been set at $572 million, up slightly from $556 million. This prediction comes with the expectation that Las Vegas Sands would maintain a steady gross gaming revenue (GGR) market share of around 24%, coinciding with its recent second-quarter performances. The new estimates reflect a less dramatic decline in Macau GGR, with a 1.5% drop now anticipated instead of the prior expectation of a 3.0% decline.

Adjustments to Marina Bay Sands Projections

On the other hand, the estimate for the Marina Bay Sands reveals a slight reduction with the EBITDA projection lowered to $508 million from $512 million due to ongoing room renovations. However, analysts foresee an upswing in expectations for the fourth quarter of 2024, indicating potential growth.

Renovations Present Opportunities for Growth

JPMorgan's compelling perspective regarding Las Vegas Sands is fueled by the expectation of fewer disruptions from ongoing renovations at the Londoner property in Macau. Following its recent reopening, the renovated casino is forecasted to enhance revenue through new hotel rooms and other revenue-generating features, which will be introduced in phases throughout the fourth quarter of 2024 and into 2025. This renovation strategy is anticipated to elevate Las Vegas Sands above its competitors in the region.

Events Boost Investor Sentiment

The successful performance during the Golden Week, alongside upcoming investor events scheduled in Singapore for November and in Macau in the spring, is further viewed as a positive influence. These events are expected to enhance investor visibility and help normalize what many analysts consider an undemanding valuation multiple of the company.

Future Growth Prospects Are Encouraging

JPMorgan's forecast suggests a mid-teens growth rate in Macau for 2025, anticipating EBITDA could soar around $2.8 billion. The investment firm also noted that Las Vegas Sands has been consistently buying back shares, with quarterly buybacks ranging from $400 to $500 million. Additionally, analysts predict a promising market in Singapore, anticipating approximately 7% growth in 2025 following robust growth of mid-teens in 2024. This trajectory is projected to be underpinned by capital expenditures and expansion in the Singaporean market.

Las Vegas Sands Faces Mixed Analyst Opinions

Recently, Las Vegas Sands Corp encountered mixed feedback from various analysts regarding its performance. While its second-quarter outcomes fell short of expectations due to renovation disruptions in both Macau and Singapore, firm Macquarie maintained its Outperform rating, emphasizing the long-term benefits arising from ongoing upgrades. Similarly, Stifel retained a Buy recommendation for Las Vegas Sands despite voiced concerns regarding operations in Macau.

Cautious Outlook from Other Analysts

Meanwhile, CFRA downgraded Las Vegas Sands from a Buy to a Hold designation, adjusting the price target down to $51 from $55. This revision indicates a more cautious perspective on the company's future positioning, considering the heavy reliance on the Macau and broader Asian markets.

Broader Market and Development Opportunities

Despite mixed ratings, Wells Fargo predicts a promising fourth quarter for Las Vegas Sands, while Mizuho Securities has raised its target price to $52, sustaining an Outperform rating. The company recorded a remarkable 24% increase in gaming revenues from its Macau operations, and it is keeping options open for new opportunities in markets like New York, Texas, and Thailand.

InvestingPro Insights Reflect Strong Performance

The recent financial data aligns with the optimistic outlook presented by JPMorgan. As compiled by InvestingPro, Las Vegas Sands reported a remarkable 68.48% revenue growth over the last twelve months, coupled with a staggering 137.26% increase in EBITDA. Such financial resilience substantiates projections for ongoing growth in key markets like Macau and Singapore.

Gross Profit Margins Indicate Operational Efficiency

InvestingPro highlights that the company has achieved gross profit margins of 76.91% over the past year, showcasing operational efficiency, particularly within its high-margin gaming operations. Furthermore, the company shows solid financial health, with liquid assets comfortably surpassing short-term liabilities, thus ensuring it can support the renovations and expansions referenced in analysts' evaluations.

Frequently Asked Questions

What recent changes have been made to Las Vegas Sands' stock target?

JPMorgan has raised the stock price target of Las Vegas Sands from $53 to $60 while keeping an Overweight rating.

What factors contributed to JPMorgan's bullish outlook on Las Vegas Sands?

The positive sentiment is based on expected growth in Macau, reduced renovation disruptions, and strong performance indicators during key operational events.

How do the renovations at Las Vegas Sands affect its financial outlook?

While renovations have caused short-term disruptions, they are anticipated to enhance future revenues and growth prospects in key markets.

What is the EBITDA projection for Las Vegas Sands in 2025?

JPMorgan forecasts Las Vegas Sands' EBITDA to be around $2.8 billion for the year 2025.

What are some of the new markets Las Vegas Sands is exploring for development?

Las Vegas Sands is looking into new opportunities in markets including New York, Texas, and Thailand.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

SOA Elects New Leaders for 2026: A Look Ahead

Updated Category News Views 0

A New Lineup for SOA's Board in 2026 On the financial frontlines, few organizations hold the clout that the Society of Actuaries (SOA) wields. With their latest round of elections completed, they've named five fresh Board members along with both a new President Elect and Vice Chair for the upcoming 2026-2027 term. These folks are gearing up to take the stage right after...

Continue Reading
Schweid & Sons Reveals New Marinated Steak Tips Line

Updated Category News Views 0

No More Prep Dilemmas: Schweid & Sons Unveils Steak Tips Packing a punch in the protein aisle, Schweid & Sons throws down the gauntlet with their latest culinary innovation — Marinated Steak Tips. These aren't just your run-of-the-mill cuts, folks. We're talking premium Tri-Tip, butcher-trimmed to perfection, and marinated in both Cajun and Teriyaki styles. It's all...

Continue Reading
Beasley and Vegas Golden Knights Partner for Broadcast

Updated Category News Views 2

Strategic Moves on the Airwaves The Vegas Golden Knights are skating into a new era of broadcasting. Teaming up with Beasley Media Group, they've inked a multiyear deal that makes the media outfit their official audio partner. Dropping the puck on this relationship means folks in Southern Nevada can catch the action on Beasley's English and Spanish stations. It's a hefty...

Continue Reading
Kansas Marijuana DUI Laws: What Drivers Must Know

Updated Category News Views 0

Navigating the Legal Maze of Marijuana DUIs Marijuana DUI, ever heard of it? Many folks in Kansas might just find themselves scratching their heads. While booze clearly shouts 'DUI' when you hit the road sauced, the green stuff doesn’t dodge that same bullet. You better believe it, Kansas doesn’t mess around when it comes to drugs behind the wheel, and marijuana is...

Continue Reading
Gray's Rise in ENR Rankings Highlights Sector Dominance

Updated Category News Views 2

Gray's Outstanding Reputation in the Construction Arena Nothing says “we're on top of our game” like snatching top slots in industry rankings, and that's precisely what Gray, the construction and engineering heavyweight, has managed to do. This firm recently secured impressive spots across ten different categories in the prestigious Engineering News-Record (ENR) Top...

Continue Reading
Claigan Webinar Tackles Prop 65 Warnings for 2028

Updated Category News Views 2

Buckle up, folks. Here comes a wake-up call for businesses playing loose with their compliance homework on California's Prop 65, thanks to Claigan's latest announcement. They're hosting a webinar on October 7, 2026, gearing up everyone who'll listen for the changes hitting the books in 2028. We’re zooming past the days of generic warnings; pretty soon, it'll be all...

Continue Reading
HiBy Unveils Cyberpunk 2077 Gaming Audio Line

Updated Category News Views 0

HiBy Hits the Gaming Scene with Cyberpunk Flair It's a wild world when audio tech and gaming collide outside of the usual suspects. HiBy's latest move is a bold pivot into the gaming universe, launching an audacious collaboration with, of all things, the cybernetic chaos of Cyberpunk 2077. You can almost feel the underlying scrappiness of Night City embedded into a couple...

Continue Reading
Colson Group Expands with Algood Acquisition

Updated Category News Views 2

A Big Move in Mobility Solutions Put on your seatbelts, because Colson Group is steering into a new lane with its acquisition of Algood Caster Innovations. This ain't just any pickup—it's a smart move that could ramp up their North American manufacturing clout and mobility solutions. You know, mergers like these don't come around by accident. Colson sees something...

Continue Reading
LifeLabs' AI Program: A Manager's New Toolbox

Updated Category News Views 2

Management In the Age of AI: New Frontiers Gone are the days when a simple software update meant staying competitive. We're in a new era, folks—one where AI isn't just a handy tool—it's reshaping entire industries. But here's the kicker: all the fancy tech in the world won't do squat without savvy managers who know how to drive adoption. Yup, that's the naked truth,...

Continue Reading
AHN Healthcare@Home Celebrates Fourth Top Workplace Win

Updated Category News Views 4

Four-Time Top Workplace Champ You want to talk consistency? Let's talk about AHN Healthcare@Home pulling in that Pittsburgh Top Workplace award four years running. It's no small feat, especially in the healthcare sector where employee burnout isn't just a buzzword—it's a daily challenge. How did a home health and hospice outfit like AHN land this honor? Well, it's all...

Continue Reading

Top 5 Most Recently Viewed Articles

BioXcel Therapeutics Collaborates with UNC on ASD Research

Updated Category News Views 118

BioXcel Therapeutics Partners with UNC for ASD Trial BioXcel Therapeutics, Inc. (NASDAQ:BTAI), renowned for its innovative approach in AI-driven drug development, is embarking on an important collaboration with the University of North Carolina at Chapel Hill. This partnership aims to assess the effectiveness and safety of BXCL501, an investigational drug for the treatment...

Continue Reading
Tong Hsing Taps SixSense for Smarter AI-Driven Manufacturing

Updated Category News Views 178

Tech Transformation Hits Semiconductor Manufacturing Every now and then, an announcement rolls out that catches the eye of industry skeptics, and the Tong Hsing Electronic and SixSense partnership is one such occasion. This collaboration, announced on February 25, 2026, isn’t just another tech-splat on the semiconductor wall; it’s a serious push toward revolutionizing...

Continue Reading
Fractal's Recognition as a Top Workplace for Women and DEI

Updated Category News Views 46

Fractal's Commitment to Building a Diverse Workplace Fractal, a renowned provider of AI solutions, has recently received significant recognition from the Great Place to Work® Institute for 2024. This acknowledgment highlights the company's unwavering dedication to creating an inclusive work environment, particularly for women and underrepresented groups. Their commitment...

Continue Reading
Sunrise Home Buyers Recognized for Excellence in Alberta Market

Updated Category News Views 113

Sunrise Home Buyers Reigns as Alberta's Top Home Buying Company Sunrise Home Buyers, a well-respected cash-for-houses company, is thrilled to announce that it has achieved the esteemed title of Alberta’s leading home buying company thanks to consistently receiving 5-star reviews on platforms like Google and Facebook. With a strong commitment to assisting homeowners who...

Continue Reading
Pfizer Investigation: Allegations of Delayed Vaccine Results

Updated Category News Views 283

House Judiciary Committee Subpoenas Pfizer's Dr. Philip Dormitzer The House Judiciary Committee is intensifying its investigation into Pfizer Inc.'s COVID-19 vaccine announcement, subpoenaing Dr. Philip Dormitzer, a former executive at the company. This inquiry examines claims that Pfizer may have intentionally withheld clinical testing results until after the 2020...

Continue Reading